European association of urology (EAU) guidelines now support the role and recommend RP to be an appropriate option for selected patients with small low volume T3 tumor, PSA <20 ng/ml, Gleason score < 8 and life expectancy of > 10 years.12 The gene discussed is KLK3; the disease is neoplasm.